Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Tian, Li ^a   Liu, Yinghui ^a   Qin, Yang ^a   Long, Shiyin ^b   Xu, Yanhua ^c   Fu, Mingde ^d  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c Chengdu Hoist Biotechnology Co LTD   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 2A; HIGH DENSITY LIPOPROTEIN 2B; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN 3A; HIGH DENSITY LIPOPROTEIN 3B; HIGH DENSITY LIPOPROTEIN 3C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREBETA1 HIGH DENSITY LIPOPROTEIN; PREBETA2 HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN; ISOPROTEIN; LIPID;

ADULT; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PROTEIN LOCALIZATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ALGORITHM; ATHEROSCLEROSIS; BLOOD; CHINA; CLASSIFICATION; CORONARY ARTERY DISEASE; HYPERLIPOPROTEINEMIA; MIDDLE AGED; PROTEIN ELECTROPHORESIS; STATISTICS;

AGED; ALGORITHMS; APOLIPOPROTEINS; ATHEROSCLEROSIS; BLOOD PROTEIN ELECTROPHORESIS; CHINA; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPIDS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROTEIN ISOFORMS; STATISTICS AS TOPIC; TRIGLYCERIDES;

EID: 77954341868     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-69     Document Type: Article

References (43)

1. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. WB Kannel JD Neaton D Wentworth HE Thomas J Stamler SB Hulley MO Kjelsberg, Am Heart J 1986 112 825 836 10.1016/0002-8703(86)90481-3 3532744
2. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. WP Castelli RJ Garrison PWF Wilson RD Abbott S Kalousdian WB Kannel, JAMA 1986 256 2835 2838 10.1001/jama.256.20.2835 3773200
3. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. T Gordon WP Castelli MC Hjortland WB Kannel TR Dawber, Am J Med 1977 62 707 714 10.1016/0002-9343(77)90874-9 193398
4. Plasma high density lipoprotein concentration and development of ischaemic heart disease. GJ Miller NE Miller, Lancet 1977 1 16 18
5. Non-HDL cholesterol, apolipoproteinA-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. PM Ridker N Rifai NR Cook G Bradwin JE Buring, JAMA 2005 94 326 333 10.1001/jama.294.3.326
6. Physiological role and clinical relevance of high-density lipoprotein subclasses. A Von Eckardstein Y Huang G Assmann, Curr Opin Lipidol 1994 5 404 416 10.1097/00041433-199412000-00003 7712045
7. Study on the immunodetection method of HDL subclasses in human serum. XW Wu MD Fu BW Liu, Chin J Arterioscler 1999 7 253 255
8. Alterations of HDL subclasses in hyperlipidemia. YH Xu MD Fu, Clin Chim Acta 2003 332 95 102 10.1016/S0009-8981(03)00138-4 12763286
9. High-density lipoprotein subfractions. DI Silverman SG Geoffery RC Pasternak, Am J Med 1993 94 636 645 10.1016/0002-9343(93)90217-D 8506891
10. 1-HDL into -migrating HDL is severely delayed in hemodialysis patients. T Miida O Miyazaki O Hanyu Y Nakamura S Hirayama I Narita F Gejyo I Ei K Tasaki Y Kohda T Ohta S Yata I Fukamachi M Okada, J Am Soc Nephrol 2003 14 732 738 10.1097/01.ASN.0000046962.43220.8A 12595510
11. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. JR Patsch JB Karlin LW Scott LC Smith AM Gotto Jr, Proc Natl Acad Sci USA 1983 80 1449 1453 10.1073/pnas.80.5.1449 6402780
12. Relationship of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. NE Miller F Hammett S Saltissi S Rao H Van Zeller J Coltart B Lewis, Br Med J 1981 282 1741 1743 10.1136/bmj.282.6278.1741
13. High density and low-density lipoprotein subfractions in survivors of myocardial infarction and control subjects. FC Ballantyne RS Clark HS Simpson D Ballantyne, Metabolism 1982 31 433 437 10.1016/0026-0495(82)90230-X 6952064
14. Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses. LQ Jia SY Long MD Fu BY Yan Y Tian YH Xu LT Gou, Metabolism 2006 55 1141 1148 10.1016/j.metabol.2006.04.004 16919530
15. Alterations of HDL subclasses in endogenous hypertriglyceridemia. LT Gou MD Fu YH Xu Y Tian BY Yan LC Yang, Am Heart J 2005 150 1039 1045 10.1016/j.ahj.2005.02.032 16290993
16. Relationship between plasma lipid concentrations and HDL subclasses. YY Yang BY Yan MD Fu YH Xu Y Tian, Clin Chim Acta 2005 354 49 58 10.1016/j.cccn.2004.11.015 15748599
17. Alterations of high-density lipoprotein subclasses in hypercholesterolemia and combined hyperlipidemia. LQ Jia MD Fu Y Tian YH Xu LT Gou HM Tian L Tian, Int J Cardiol 2007 120 331 337 10.1016/j.ijcard.2006.10.007 17166608
18. The prospective cardiovascular Munster (PROCAM) study: Identification of high-risk individuals for myocardial infarction and the role of high-density lipoprotein. G Assmann H Schulte H Funke A Von Eckardstein U Seedorf, High Density lipoproteins and Atherosclerosis II ICS 826, Amsterdam, Netherlands, Excerpta Medica, Miller NE, 1989 51 65
19. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. HN Hodis WJ Mack SP Azen P Alaupovic JM Pogoda L LaBree LC Hemphill DM Kramsch DH Blankenhorn, Circulation 1994 90 42 49 8026027
20. On-treatment levels of HDL-C and the ratio of LDL-C/HDL-C as predictors of cardiovascular events in the Treating to New Targets (TNT) Study. P Barter AM Gotto JC LaRosa J Maroni M Szarek SM Grundy JJ Kastelein V Bittner JC Fruchart, Presented at the American College of Cardiology 55th Annual Scientific Session, Atlanta, March 11-14, 2006. J Am Coll Cardiol 2006 47 Suppl 4 298A 298A
21. Triglycerides are major determinants of cholesterol esterification/ transfer and HDL remodeling in human plasma. T Murakami S Michelagnoli R Longhi G Gianfranceschi F Pazzucconi L Calabresi CR Sirtori G Franceschini, Arterioscler Thromb Vasc Biol 1995 15 1819 1828 7583561
22. Altered particle size distribution of apolipoproteinA-I-containing lipoproteins in subjects with coronary artery disease. MC Cheung BG Brown AC Wolf JJ Albers, J Lipid Res 1991 32 383 394 1906084
23. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men. I Lemieux B Lamarche C Couillard A Pascot B Cantin J Bergeron GR Dagenais JP Després, Arch Intern Med 2001 161 2685 2692 10.1001/archinte.161.22.2685 11732933
24. 2cholesterol. A Zambon SS Deeb JE Hokanson BG Brown JD Brunzell, Arterioscler Thromb Vasc Biol 1998 18 1723 1729 9812910
25. Purification and characterization of a human plasma cholesteryl ester transfer protein. CB Hesler TL Swenson AR Tall, J Biol Chem 1987 262 2275 2282 3818596
26. Plasma cholesteryl ester transfer protein. AR Tall, J Lipid Res 1993 34 1255 1274 8409761
27. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein(HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. A Barrans X Collet R Barbaras B Jaspard J Manent C Vieu H Chap B Perret, J Biol Chem 1994 269 11572 11577 8157689
28. Comparison of Once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). HE Bays CA Dujovne ME McGovern TE White ML Kashyap AG Hutcheson JR Crouse Advicor Versus Other Cholesterol Modulating Agents Trial Evaluation, Am J Cardiol 2003 91 667 672 10.1016/S0002-9149(03)00007-9 12633795
29. Compromised LCAT function is associated with increased atherosclerosis. GK Hovingh BA Hutten AG Holleboom W Petersen P Rol A Stalenhoef AH Zwinderman ED Groot JP Kastelein JA Kuivenhoven, Circulation 2005 112 879 884 10.1161/CIRCULATIONAHA.105.540427 16061733
30. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. SE Borggreve R De Vries RP Dullaart, Eur J Clin Invest 2003 33 1051 1069 10.1111/j.1365-2362.2003.01263.x 14636288
31. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. G Assmann H Schulte H Funke A Von Eckardstein, Eur Heart J 1998 19 suppl M 8 M14 9821011
32. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. V Manninen L Tenkanen P Koskinen JK Huttunen M Manttari OP Heinonen MH Frick, Circulation 1992 85 37 45 1728471
33. Summary estimates of cholesterol used to predict coronary heart disease. WP Castelli RD Abbott PM McNamara, Circulation 1983 67 730 734 6825228
34. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. U Goldbourt S Yaari JH Medalie, Arterioscler Thromb Vasc Biol 1997 l17 107 113
35. Effect of dietary acids 2 on serum lipids and lipoproteins. A meta-analysis of 27 trials. PP Mensink MB Katan, Arterioscler Throm Vasc Biol 1992 12 911 919
36. Effect of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects The Study Protocol1. HN Ginserg P Kris-Etherton B Dennis PJ Elmer A Ershow M Lefevre T Pearson P Roheim R Ramakrishnan R Reed K Stewart K Phillips N Anderson, Arterioscler Throm Vasc Biol 1998 18 441 449
37. A low-fat diet decreases high density lipoprotein(HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. EA Brinton S Eisenberg JL Breslow, J Clin Invest 1990 85 144 151 10.1172/JCI114405 2104877
38. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. F Tato GL Vega, Arterioscler Throm Vasc Biol 1995 15 112 120
39. on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
40. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. GR Warnick T Nguyen AA Albers, Clin Chem 1985 31 217 222 2578337
41. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. WT Friedewald RI Levy DS Fredrickson, Clin Chem 1972 18 499 502 4337382
42. Immunological assays of apolipoproteins in plasma: methods and instrumentation. C Labeur J Shepherd M Rosseneu, Clin Chem 1990 36 591 597 2182220
43. Immunoassay of human plasma apolipoproteins and clinical applications. BW Liu, Lipoproteins and Atherosclerosis Beijing, People's Health Press, Wang KQ, 1995 359 368